Rotavirus vaccination could prevent a substantial number of RVGE cases, visits, hospitalizations and deaths in children. To be considered a cost-effective use of government health spending, the vaccine price would need to be reduced and/or lower health system delivery cost assumptions would need to be justified.
No takes yet. Share an insight, caveat, or question.
Shaheen et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: